drugset / Trial / NCT05634499
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.
Timeline
- Start
- 2023-06-27
- Primary completion
- 2026-08-28
- Completion
- 2026-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Giredestrant | Small molecule | 30 mg | Oral |